Repligen to acquire BioLife Solutions for $31 per share, or $1.5B
Repligen (RGEN) agreed to acquire BioLife Solutions (BLFS) for about $1.5B enterprise value, paying $31.00 per BLFS share. Consideration is 64% Repligen stock and 36% cash, including $11.25 cash and 0.1442 RGEN shares per BLFS share. Deal closes in Q4 2026, subject to approvals. Repligen expects at least $20M synergies in year one and $30M in year two.
How this was made
The 30-second read
Why it matters
The deal introduces a clear valuation anchor ($31 per BLFS share) and a defined consideration structure (64% stock, 36% cash), plus quantified accretion and synergy expectations that can drive near-term repricing and deal-spread trading.
Market read
Definitive M&A with a stated premium and quantified synergy/accretion creates actionable deal-spread and execution-risk trading for both RGEN and BLFS.
What to watch
Key swing factors are regulatory approval, BioLife stockholder vote, and whether the modest revenue synergy assumption leaves meaningful dilution or margin risk not fully captured in the stated accretion.
Background
Repligen and BioLife Solutions entered a definitive agreement for a cash-and-stock acquisition valued at about $1.5B enterprise value.
Ticker impact
Repligen agreed to acquire BioLife Solutions for about $1.5B, using 64% stock and 36% cash, with accretion targets and synergy estimates.
Likely positive bias while deal approval and Q4 2026 closing remain the primary overhang; volatility around regulatory/stockholder approvals.
The article discloses definitive M&A consideration mix, implied premium, and quantified accretion and synergy expectations, which are direct inputs to valuation and risk.
BioLife Solutions will be acquired for $31 per share, including $11.25 cash and 0.1442 RGEN shares, implying a 24% to 90% premium.
Supportive for BLFS as long as deal terms hold; spread compression/expansion likely as approval and regulatory milestones approach.
The article provides definitive per-share consideration and premium range, which directly drives expected value and trading behavior for BLFS.
Market effects
Signals consolidation in bioprocessing/biopharma services, potentially affecting deal expectations and valuation benchmarks for peers.
Primarily US-listed biotech/healthcare M&A sentiment; limited direct regional spillover beyond US small/mid-cap complex.
Could influence global bioprocessing M&A appetite, but the disclosed impact is mainly on the two US-listed companies.
Counterpoint
Accretion and synergy targets may be optimistic; if integration costs or cross-selling traction disappoint, the stock could underperform despite the premium.
Key entities
- acquirerRepligen
Agreed to acquire BioLife Solutions for about $1.5B EV, using 64% RGEN stock and 36% cash.
- targetBioLife Solutions
Will be acquired for $31 per share, including $11.25 cash and 0.1442 shares of RGEN.
